SW780 Xenograft Model Service for Bladder Cancer

The SW780 Xenograft Model Service for Bladder Cancer provides a robust, clinically relevant preclinical platform for evaluating novel therapeutics against luminal-papillary urothelial carcinoma. Alfa Cytology delivers fully customizable SW780 xenograft studies---from model establishment and treatment administration to longitudinal tumor monitoring and histopathological endpoint analysis---enabling pharmaceutical and biotechnology partners to generate high-quality efficacy data with accelerated turnaround times.

Overview of SW780 Xenograft Model for Bladder Cancer

SW780 is a well-characterized human bladder cancer cell line originally derived from a stage I transitional cell carcinoma (urothelial carcinoma) of the bladder in an 80-year-old female patient. It is classified within the luminal-papillary molecular subtype, exhibiting epithelial morphology, adherent growth properties, and expression of urothelial differentiation markers such as cytokeratins and uroplakin. The cell line harbors an oncogenic FGFR3-BAIAP2L1 gene fusion and TP53 mutations, making it particularly relevant for studying FGFR-targeted therapies and luminal subtype biology. SW780 cells retain tumorigenic capacity in immunocompromised mice, forming subcutaneous xenografts that recapitulate key histological and molecular features of luminal bladder cancer, including Nectin-4 overexpression.

In preclinical research, SW780 xenografts have been extensively utilized to evaluate antibody-drug conjugates, FGFR inhibitors, photodynamic therapies, and oncolytic viral vectors. The model demonstrates consistent tumor take rates and measurable growth kinetics, supporting both subcutaneous and orthotopic implantation strategies. Its luminal molecular signature, characterized by high Nectin-4 expression and FGFR3 fusion dependency, positions the SW780 xenograft as a representative model for testing therapeutics targeting luminal-papillary bladder cancer, including agents such as enfortumab vedotin and next-generation FGFR inhibitors.

Figure 1. EGCG enhanced the apoptosis induction effect of DOX in SW780 and T24 cells. (Luo, Ke-Wang, et al., 2020)

Cell Line Information: SW780

SW780 is a human urothelial carcinoma cell line with well-defined molecular and phenotypic characteristics. The following table summarizes essential cell line parameters relevant to xenograft model development and preclinical study design.

Our Services

Alfa Cytology offers end-to-end SW780 xenograft model services tailored to your preclinical research objectives. Our team manages every stage of the study lifecycle---from cell line authentication and health monitoring to tumor implantation, treatment administration, and comprehensive endpoint analysis---ensuring reproducible, publication-ready data delivered on schedule. Whether you require standard subcutaneous xenografts, orthotopic bladder models, or bioluminescence-enabled real-time tumor tracking, Alfa Cytology provides the technical expertise and quality assurance your program demands.

Workflow of SW780 Xenograft Model Construction

Construction of the SW780 xenograft model follows a standardized, quality-controlled workflow designed to ensure consistent tumor establishment, reliable growth kinetics, and valid pharmacological readouts. Each step is executed under IACUC-approved protocols with rigorous documentation and quality checkpoints.

1. Cell Line Preparation and Authentication: SW780 cells are expanded from authenticated stocks (ATCC CRL-2169) and verified by STR profiling prior to implantation. Mycoplasma testing is performed to ensure culture purity. Cells are harvested during logarithmic growth phase to maximize viability and tumorigenic potential.
2. Cell Suspension Formulation: Harvested cells are washed with sterile PBS, counted, and resuspended at the desired concentration (typically 1x10^6 to 2x10^6 cells per 100--200 uL). For enhanced tumor take rates, cells may be mixed 1:1 with reduced-growth-factor Matrigel or similar extracellular matrix support prior to inoculation.
3. Animal Preparation and Implantation: Immunocompromised mice (nude, NSG, or SCID; 5--8 weeks old) are acclimatized and randomized into study groups. Under appropriate anesthesia, the cell suspension is injected subcutaneously into the lower flank using a sterile insulin syringe. Alternatively, orthotopic implantation into the bladder wall may be performed for site-specific studies.
4. Tumor Monitoring and Randomization: Tumors are monitored by palpation and/or non-invasive imaging (caliper measurement, bioluminescence, or micro-CT). Once tumors reach a predetermined volume (typically 100--200 mm^3), mice are randomized into treatment and control cohorts to minimize inter-group variability.
5. Treatment Administration: Test articles are administered according to the study protocol---via intraperitoneal, intravenous, oral, or intravesical routes---at defined dosing schedules. Vehicle controls receive matched formulation without active compound. Body weight and clinical signs are recorded throughout the dosing period.
6. Endpoint Assessment and Tissue Collection: At study termination, tumors are excised, weighed, and measured. Tumor growth inhibition (TGI) is calculated relative to vehicle controls. Tissues are fixed for histopathology (H&E, IHC for Ki67, PCNA, cleaved caspase-3), snap-frozen for molecular analysis, or processed for pharmacokinetic studies as required.

Figure 2. SW780 xenograft model construction workflow.

Case Study-SW780 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous SW780 xenografts in immunocompromised mice to evaluate the efficacy of a novel therapeutic candidate targeting the Nectin-4 signaling axis. Following successful tumor engraftment and randomization, animals received the investigational agent according to a multi-dose schedule. Longitudinal tumor measurements demonstrated dose-dependent tumor growth inhibition compared to vehicle-treated controls, with corresponding reductions in tumor weight and volume at study endpoint. Histopathological analysis revealed decreased Ki67 and PCNA proliferation indices alongside increased apoptotic markers in treated tumors, supporting the mechanism of action. Detailed quantitative data, including tumor growth curves, body weight trajectories, and pharmacodynamic biomarker results, are available upon request under confidentiality agreement.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver SW780 xenograft studies that meet the highest standards of preclinical research. Our integrated service model ensures seamless execution from study design to final report.

• Authenticated cell lines with verified STR profiles and mycoplasma-free certification, ensuring genetic fidelity across every study.
• Customizable study designs including subcutaneous, orthotopic, and bioluminescence-enabled models to match specific research questions.
• Real-time tumor monitoring capabilities via digital caliper, IVIS imaging, and micro-CT for precise pharmacodynamic assessments.
• Comprehensive endpoint analysis encompassing histopathology, immunohistochemistry, biomarker quantification, and pharmacokinetic sampling.
• IACUC-approved protocols and AAALAC-accredited facilities guaranteeing ethical standards and regulatory compliance.
• Dedicated project management with transparent reporting, ensuring on-time delivery and data packages ready for IND-enabling submissions.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated SW780 xenograft model? Contact Alfa Cytology today to discuss your study requirements, receive a customized proposal, and partner with a CRO committed to delivering reliable, actionable preclinical data. Please reach out to us today via our inquiry form or email to learn more about our SW780 Xenograft Model services.

For research use only. Not intended for any clinical use.